Apellis Pharmaceuticals Inc
NASDAQ:APLS
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Price:
22.25
USD
-0.13%
Market Closed
Market Cap:
$2.8B
Balance Sheet
Balance Sheet Decomposition
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Balance Sheet
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
5
|
14
|
36
|
25
|
176
|
176
|
352
|
566
|
640
|
552
|
351
|
411
|
|
| Cash Equivalents |
5
|
14
|
36
|
25
|
176
|
176
|
352
|
566
|
640
|
552
|
351
|
411
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
312
|
60
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
1
|
2
|
1
|
1
|
2
|
0
|
0
|
10
|
29
|
224
|
272
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
8
|
206
|
265
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
22
|
18
|
7
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
86
|
146
|
81
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
5
|
25
|
21
|
40
|
97
|
53
|
44
|
25
|
|
| Total Current Assets |
5
|
14
|
38
|
27
|
182
|
202
|
373
|
917
|
824
|
720
|
766
|
789
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
16
|
25
|
26
|
25
|
21
|
19
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
19
|
32
|
16
|
1
|
77
|
|
| Total Assets |
5
N/A
|
14
+175%
|
38
+167%
|
27
-28%
|
182
+565%
|
204
+12%
|
389
+91%
|
961
+147%
|
882
-8%
|
760
-14%
|
789
+4%
|
885
+12%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
1
|
3
|
3
|
4
|
10
|
8
|
9
|
17
|
37
|
38
|
39
|
|
| Accrued Liabilities |
0
|
0
|
1
|
1
|
3
|
5
|
57
|
116
|
107
|
101
|
134
|
147
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
4
|
8
|
30
|
76
|
0
|
|
| Total Current Liabilities |
1
|
1
|
3
|
4
|
7
|
17
|
66
|
128
|
132
|
168
|
248
|
186
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
26
|
25
|
143
|
359
|
534
|
408
|
333
|
453
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
147
|
269
|
17
|
14
|
14
|
18
|
|
| Total Liabilities |
1
N/A
|
1
+57%
|
3
+191%
|
4
+13%
|
33
+822%
|
43
+28%
|
355
+733%
|
756
+113%
|
683
-10%
|
590
-14%
|
594
+1%
|
657
+10%
|
|
| Equity | |||||||||||||
| Common Stock |
17
|
36
|
77
|
92
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
14
|
25
|
71
|
98
|
149
|
277
|
582
|
926
|
1 657
|
2 309
|
2 837
|
3 035
|
|
| Additional Paid In Capital |
1
|
2
|
29
|
30
|
298
|
438
|
616
|
1 131
|
1 857
|
2 480
|
3 036
|
3 267
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
3
|
3
|
|
| Total Equity |
5
N/A
|
13
+193%
|
35
+165%
|
24
-32%
|
149
+526%
|
161
+8%
|
34
-79%
|
205
+498%
|
199
-3%
|
170
-14%
|
195
+14%
|
229
+17%
|
|
| Total Liabilities & Equity |
5
N/A
|
14
+175%
|
38
+167%
|
27
-28%
|
182
+565%
|
204
+12%
|
389
+91%
|
961
+147%
|
882
-8%
|
760
-14%
|
789
+4%
|
885
+12%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
49
|
49
|
49
|
49
|
50
|
56
|
64
|
76
|
98
|
111
|
120
|
124
|
|
Switch to:
Switch to:
See Also
Discover More
